X

Trial Profile

A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms RROPE

Most Recent Events

07 Feb 2024 Status changed from active, no longer recruiting to completed.
18 Feb 2023 Initial results of radium-223 and radiotherapy assessing efficacy and safety in untreated patients with oligometastatic prostate cancer, presented at the 2023 Genitourinary Cancers Symposium.
14 Dec 2022 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com